Given the increasing prevalence of metabolic defects associated with deregulated glucose and lipid metabolism and with mitochondria dysfunction, targeting CD36 with GHRPs appears to be a safe option for the treatment of metabolic disorders. This evidence concerns the gene CD36 and metabolic disease.